We further divided the tested population by age, and found that younger patients (<55 years) with the AG/GG genotypes of MALAT1 rs619586 had a decreased risk of HCC under the codominant model (AG vs. AA: AOR, 0.289; 95% CI, 0.108–0.773; p = 0.013) and dominant model (AG + GG vs. AA: AOR, 0.286; 95% CI, 0.107–0.765; p = 0.013) (Table 3), while no associations were observed in elderly HCC patients (≥55 years) (data not shown). Here, MALAT1 is linked to hepatocellular carcinoma.